The focus on drug pricing – and in particular Democratic presidential nominee Hillary Clinton’s plan, if elected, to institute a panel that would take on “unjustified” price hikes – prompted Morgan Stanley to issue a series of reports on how this policy would affect the pharmaceutical industry overall.

Thursday’s report looks at what constitutes a “normal” or an “excessive” price hike by looking at the top 269 drugs price increases over the past seven years.

Morgan Stanley singled out the drugs that had increased more than 50% in price since 2009 and in particular those that have gone up at least 200% to 400%, a group of drugs that haven’t received as much attention as the EpiPen or some of Valeant’s portfolio that’s been called out over the last year.